[Form 4] Cidara Therapeutics, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Cidara Therapeutics (CDTX) – Form 4 insider filing: Director Joshua Resnick reported the receipt of a pro-rated annual stock-option award on 18 June 2025. The grant covers 5,079 options to purchase CDTX common shares at an exercise price of $21.31 per share. These options will vest in full on the earlier of 18 June 2026 or the day prior to the company’s 2026 annual shareholder meeting, and they expire on 17 June 2035.

Resnick holds the options for the benefit of RA Capital Healthcare Fund, L.P. under an arrangement that requires any net proceeds from exercise to be turned over to RA Capital Management. As a result, he disclaims beneficial ownership of both the options and the underlying shares. No open-market purchases or sales of common stock were reported, and Resnick’s direct derivative holdings now total 5,079 options.

Insights

Corporate Governance Analyst

TL;DR: Routine director option grant; negligible governance or valuation impact.

This Form 4 reflects a normal-course, pro-rated annual equity award to a board member. The grant size—5,079 options—is modest, and the one-year cliff vest aligns with standard director compensation practices. Because proceeds flow to RA Capital, the filing is more procedural than economic for the individual. There is no dilution beyond what investors would already expect from the company’s equity incentive plan, and no open-market activity to signal insider sentiment. Overall, the disclosure is a compliance event with neutral impact on governance or share value perceptions.

Portfolio Manager

TL;DR: Small, non-cash option grant—no trading signal for CDTX.

The award’s strike price of $21.31 and 10-year term are typical. Given CDTX’s micro-cap status, the 5,079-share option block is immaterial to float and has no immediate P&L consequences. The absence of any share sale or purchase suggests no directional view by the insider. Investors can treat this as a routine administrative filing with no portfolio-level action warranted.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Resnick Joshua

(Last) (First) (Middle)

C/O CIDARA THERAPEUTICS, INC.

6310 NANCY RIDGE DRIVE SUITE 101

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Cidara Therapeutics, Inc. [ CDTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/18/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$21.31	06/18/2025		A		5,079(1)		(2)	06/17/2035	Common Stock	5,079	$0	5,079	D(3)

Explanation of Responses:

1. Annual director stock option grant of 11,100 shares is pro-rated based on the number of days served on the Issuer's board of directors prior to the grant date divided by 365 days.

2. The shares subject to the option shall vest on the earlier of (i) June 18, 2026 or (ii) the day prior to the date of the Issuer's 2026 annual meeting of stockholders.

3. Under the Reporting Person's arrangement with RA Capital Management, L.P. (the "Adviser"), the Reporting Person holds the option for the benefit of the RA Capital Healthcare Fund, L.P. (the "Fund"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received upon exercise of the option, which will offset advisory fees owed by the Fund to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock.

Remarks:

	/s/ Shane Ward, Attorney-in-Fact	06/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many Cidara Therapeutics (CDTX) options were granted to Joshua Resnick?

The Form 4 shows a grant of 5,079 stock options.

What is the exercise price of the newly granted CDTX options?

The options have an exercise price of $21.31 per share.

When do the options granted to Director Resnick vest?

They vest on the earlier of 18 June 2026 or the day before CDTX’s 2026 annual shareholders’ meeting.

Did the Form 4 report any sale or purchase of CDTX common stock?

No. The filing only reports an option grant; no common shares were bought or sold.

Why does Joshua Resnick disclaim beneficial ownership of the options?

Under an arrangement with RA Capital Management, any proceeds from the options must be turned over to the fund, so he disclaims ownership.

What is the expiration date of the granted CDTX options?

The options expire on 17 June 2035.